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Competition for organic anion
transporters in chronic renal
disease
To the Editor: In their mini review, Meyer and Hostetter1
review recent evidence that uremic toxins such as indoxyl
sulfate and p-cresyl sulfate are produced by colonic bacteria
and suggest that suppressing their production might beneﬁt
patients with renal failure.
Evidence that uremic solutes are secreted, rather than
ﬁltered, using organic anion transporters2,3 may create a new
paradigm in treating patients with chronic renal failure.
Smith wrote, ‘In tubular excretiony apparently all substances
share a common element in one of two transport systemsy
This is presumably a result of competitiony since it is freely
reversible’.4 The possibility that many drugs compete for the
secretion of indoxyl sulfate or other uremic toxins broadens
greatly the range of drugs that should be used with caution in
patients with uremia or less-advanced stages of renal failure.
Rather than focus on guidelines that depend on estimated
glomerular ﬁltration rate, prescribing for patients with
chronic renal failure should take into consideration possible
competition for organic anion transport.
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The Authors Reply: Like Dr Lowenstein,1 we are intrigued
by the possibility that impaired secretion of toxic compounds
contributes to uremic illness. Competition for tubular
transport may cause both natural waste solutes and
pharmaceutical metabolites to accumulate out of proportion
to the reduction in glomerular ﬁltration rate (GFR). As Dr
Lowenstein notes, the assumption that some of these secreted
compounds are toxic can explain why uremic symptoms are
not closely correlated with creatinine and other GFR markers.
James Shannon, a student of Homer Smith, who became
Director of the NIH, raised these points many years ago and
concluded, ‘The answer to this question must await the
further identiﬁcation of those substances which make up the
unknown portion of the urinary constituents’.2 So far,
however, we have compiled only a limited catalog of secreted
compounds and know very little about their individual effects.
In addition to their transport across the renal tubules, the
transport of organic ions across other barriers may be involved
in uremic illness. For example, hepatic clearance of some drugs
is reduced in end-stage renal disease patients due at least in
part to impaired hepatic transport of organic ions.3 Impaired
organic ion transport across the blood–brain barrier could
contribute to uremic encephalopathy.4 The organic ion trans-
porters are widely distributed and the accumulation of trans-
ported solutes due to kidney failure could therefore interfere
with multiple physiological processes.
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Interstitial mononuclear infiltrates
in murine a3(IV)-NC1–induced
nephropathy: harbingers of renal
failure?
To the Editor: Whereas the noncollagenous domain 1 of
a3(IV) collagen (a3(IV)-NC1) is the major target of Good-
pasture autoantibodies in anti-glomerular basement mem-
brane (GBM) glomerulonephritis, DBA/1 mice immunized
with a3(IV)-NC1 develop massive albuminuria progressing to
nephrotic syndrome. Kidney histopathology shows ﬁne granular
GBM deposition of immunoglobulin G and C3, GBM thick-
ening with ‘spike’ reaction, subepithelial electron-dense deposits,
and podocyte foot process effacement, but minimal glomer-
ular inﬂammation.1–3 These clinical and morphological ﬁndings
recapitulate human membranous nephropathy rather than
anti-GBM glomerulonephritis. This unexpected phenotype
may be due to a subepithelial planted antigen, consistent with
the ﬁne granular deposition of exogenous antigen in the
capillary loops.3 An elegant recent study comprehensively
characterized tubulointerstitial inﬁltrates of macrophages and
CD4(þ ) T helper (Th)1 and Th17 cells in the late stages of
a3(IV)-NC1–induced nephropathy.1 This may reﬂect a true
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